高通量血液透析对透析患者VEGF、ET-1的影响

发布时间：2018-03-20 03:28

本文选题：血液透析　切入点：心血管疾病　出处：《山西医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的:通过观察高通量血液透析对透析患者VEGF及ET-1水平的影响,以便更好地保护透析患者血管内皮功能,从而使心血管疾病的风险降低,为高通量血液透析的应用提供有利证据。方法:选择2015年9月至2016年10月于山西医科大学第一医院血净中心行规律血液透析治疗的患者70例,符合入选标准的有40例,分为A组与B组,A组:低通量血液透析;B组:高通量血液透析,每组20例患者,两个组都每周3次规律进行血液透析治疗,每次4个小时,治疗6个月。测定两个组在治疗6个月前后血清中Scr、BUN、UA、VEGF及ET-1的水平。观察两个组在治疗前与治疗后各指标的变化情况。经正态性检验,均数±标准差(x±S)描述符合正态分布的数据。配对t检验用于自身对照,LSD法用于组间两两的比较,卡方检验用于分类计数资料的组间比较,分析P0.05统计学差异有显著性。结果:1.对两组患者的年龄、性别、原发病进行比较,结果未见差别(P0.05);2.两组患者血Scr、BUN、UA、VEGF及ET-1在治疗前无差别(P0.05);3.治疗6个月后,A、B组血清Scr、BUN、UA、VEGF、ET-1均比6个月前有改变,具有统计学差异(P0.05);4.治疗6个,A、B组的血清Scr、BUN、UA均降低,且两组6个月前后差值无显著差别(P0.05);5.治疗6个月后,与A组比较,B组可明显降低血清中VEGF及ET-1水平,两者具有显著差别(P0.01)。结论:在清除血清Scr、BUN、UA等方面,高通量血液透析与低通量血液透析有相同的优势,但高通量血液透析可以明显降低血清VEGF及ET-1的水平,从而有助于改善血管内皮功能,减少心血管疾病,延长患者寿命。
[Abstract]:Objective: to observe the effect of high flux hemodialysis on the levels of VEGF and ET-1 in dialysis patients in order to protect vascular endothelial function and reduce the risk of cardiovascular disease. Methods: from September 2015 to October 2016, 70 patients who were treated with regular hemodialysis in Xuejing Center, first Hospital of Shanxi Medical University, met the inclusion criteria. The patients were divided into two groups: group A and group B: low flux hemodialysis group B: high flux hemodialysis with 20 patients in each group. The two groups received regular hemodialysis three times a week for 4 hours. After 6 months of treatment, the serum levels of Scr-BUNU UAA and ET-1 in the two groups were measured before and after 6 months of treatment. The changes of the indexes before and after treatment in the two groups were observed. Mean 卤standard deviation x 卤S) is used to describe data consistent with normal distribution. Paired t test is used for comparison between two groups by self-control LSD method, and chi-square test is used for comparison of classified counting data. Results: 1. The age, sex and primary disease of the two groups were compared. Results there was no significant difference between the two groups (P < 0.05). There was no difference between the two groups before treatment. After 6 months of treatment, the serum levels of Scr-BUNU UAV VEGFFN-1 in group A were all changed compared with those before 6 months, and there was statistical difference between the two groups (P 0.05), and the serum levels of Scr-BUNA in group A were lower than those in group A (P < 0.05), and the levels of ET-1 in group A were significantly lower than those in group A (P < 0.05) after 6 months of treatment. There was no significant difference in the difference between the two groups before and after 6 months. After 6 months of treatment, the serum levels of VEGF and ET-1 in group B were significantly lower than those in group A. High flux hemodialysis has the same advantages as low flux hemodialysis, but high flux hemodialysis can obviously reduce the levels of serum VEGF and ET-1, thus help to improve vascular endothelial function, reduce cardiovascular disease and prolong the life span of patients.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R692.5

【参考文献】